As of November 7, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Inhibikase Therapeutics, Inc. The largest reported stake is ADAR1 Capital Management, LLC's, at 9.9%. 18 filings are on record since August 13, 2025 (Schedule 13G/A, May 15, 2026).
Sell to companies like Inhibikase Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 10,320,875 · Sole dispositive: 0 · Shared dispositive: 10,320,875 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Nantahala Capital Management, LLC · Sole voting: 0 · Shared voting: 5,810,487 · Sole dispositive: 0 · Shared dispositive: 5,810,487 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Sands Capital Life Sciences Pulse Fund II, L.P. · Sole voting: 0 · Shared voting: 13,018,965 · Sole dispositive: 0 · Shared dispositive: 13,018,965 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 14,653,994 · Sole dispositive: 0 · Shared dispositive: 14,653,994 · SCHEDULE 13G/A, 2026-07-31
- · Reporting person: BlackRock, Inc. · Sole voting: 7,680,732 · Shared voting: 0 · Sole dispositive: 7,768,004 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-28
Inhibikase Therapeutics, Inc. has 18 Schedule 13D or 13G filings on record since 2025-08-13. 8 holders' latest filing reports 5% or more of common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 9.9% | 13,860,028 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Fairmount Funds Management LLC | 9.9% | 12,461,101 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Commodore Capital LP | 9.9% | 14,054,940 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| RA Capital Management, L.P. | 9.9% | 14,653,994 | SCHEDULE 13G/A, 2026-07-31 | 2026-07-29 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 9.3% | 13,018,965 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Perceptive Advisors LLC | 6.9% | 10,320,875 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Trails Edge Capital Partners, LP | 6.1% | 8,057,345 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| BlackRock, Inc. | 5.9% | 7,768,004 | SCHEDULE 13G, 2026-07-28 | 2026-06-30 |
| Nantahala Capital Management, LLC | 4.3% | 5,810,487 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Inhibikase Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Inhibikase Therapeutics, Inc. and the records around it.
Inhibikase Therapeutics, Inc. elsewhere on the record
- Leadership changes Oct 2026
- Who owns it
Companies that share a holder
- Sands Capital Life Sciences Pulse Fund II, L.P. also filed stake reports on 3 other companies: Acrivon Therapeutics, Inc. (Aug 2026), Alamar Biosciences, Inc. (Jul 2026), Beta Bionics, Inc. (Aug 2025)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
- Trails Edge Capital Partners, LP also filed stake reports on 16 other companies: Avalo Therapeutics, Inc. (Oct 2026), Sol-Gel Technologies Ltd. (Oct 2026), Contineum Therapeutics, Inc. (Oct 2026)
Watch Inhibikase Therapeutics, Inc.
Get an email when Inhibikase Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Inhibikase Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Inhibikase Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inhibikase Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | 0 | 14,653,994 | 0 | 14,653,994 | SCHEDULE 13G/A, 2026-07-31 |
| Peter Kolchinsky | 0 | 14,653,994 | 0 | 14,653,994 | SCHEDULE 13G/A, 2026-07-31 |
| Rajeev Shah | 0 | 14,653,994 | 0 | 14,653,994 | SCHEDULE 13G/A, 2026-07-31 |
| RA Capital Healthcare Fund, L.P. | 0 | 14,653,994 | 0 | 14,653,994 | SCHEDULE 13G/A, 2026-07-31 |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 0 | 13,018,965 | 0 | 13,018,965 | SCHEDULE 13G/A, 2026-08-13 |
| Sands Capital Alternatives, LLC | 0 | 13,018,965 | 0 | 13,018,965 | SCHEDULE 13G/A, 2026-08-13 |
| Sands Frank M. | 0 | 13,018,965 | 0 | 13,018,965 | SCHEDULE 13G/A, 2026-08-13 |
| Perceptive Advisors LLC | 0 | 10,320,875 | 0 | 10,320,875 | SCHEDULE 13G/A, 2026-08-14 |
| Joseph Edelman | 0 | 10,320,875 | 0 | 10,320,875 | SCHEDULE 13G/A, 2026-08-14 |
| Perceptive Life Sciences Master Fund, Ltd. | 0 | 10,320,875 | 0 | 10,320,875 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 7,680,732 | 0 | 7,768,004 | 0 | SCHEDULE 13G, 2026-07-28 |
| Nantahala Capital Management, LLC | 0 | 5,810,487 | 0 | 5,810,487 | SCHEDULE 13G/A, 2026-08-14 |
| Wilmot B. Harkey | 0 | 5,810,487 | 0 | 5,810,487 | SCHEDULE 13G/A, 2026-08-14 |
| Daniel Mack | 0 | 5,810,487 | 0 | 5,810,487 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Inhibikase Therapeutics, Inc. by CUSIP 45719W205 and gives its principal executive office as 1000 N. West Street, Suite 1200, Wilmington, DE 19801 (SCHEDULE 13G/A, 2026-08-14).
What the percentages are based on
Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage is 9.99%.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-07-31
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Sands Capital Life Sciences Pulse Fund II, L.P. | 14.7% | SCHEDULE 13G/A |
| 2025-08-14 | ADAR1 Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2025-12-31 | Trails Edge Capital Partners, LP | 5.1% | SCHEDULE 13G |
| 2026-02-13 | Nantahala Capital Management, LLC | 5.68% | SCHEDULE 13G/A |
| 2026-02-13 | Sands Capital Life Sciences Pulse Fund II, L.P. | 10.8% | SCHEDULE 13G/A |
| 2026-02-17 | Fairmount Funds Management LLC | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | ADAR1 Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | Perceptive Advisors LLC | 9.99% | SCHEDULE 13G/A |
| 2026-05-15 | ADAR1 Capital Management, LLC | 9.9% | SCHEDULE 13G/A |
| 2026-05-15 | Perceptive Advisors LLC | 8.9% | SCHEDULE 13G/A |
| 2026-05-15 | Trails Edge Capital Partners, LP | 6.1% | SCHEDULE 13G/A |
| 2026-05-15 | Commodore Capital LP | 9.9% | SCHEDULE 13G/A |
| 2026-07-17 | RA Capital Management, L.P. | 15.9% | SCHEDULE 13G |
| 2026-07-28 | BlackRock, Inc. | 5.9% | SCHEDULE 13G |
| 2026-07-31 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-08-13 | Sands Capital Life Sciences Pulse Fund II, L.P. | 9.3% | SCHEDULE 13G/A |
| 2026-08-14 | Nantahala Capital Management, LLC | 4.3% | SCHEDULE 13G/A |
| 2026-08-14 | Perceptive Advisors LLC | 6.9% | SCHEDULE 13G/A |
Questions about who owns Inhibikase Therapeutics, Inc.
Who owns Inhibikase Therapeutics, Inc.?
On this page, 8 holders' latest ownership filings report 5% or more of Inhibikase Therapeutics, Inc.: ADAR1 Capital Management, LLC (9.9%, Schedule 13G/A, filed 2026-05-15), Fairmount Funds Management LLC (9.9%, Schedule 13G/A, filed 2026-02-17), Commodore Capital LP (9.9%, Schedule 13G/A, filed 2026-05-15), RA Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-07-31) and Sands Capital Life Sciences Pulse Fund II, L.P. (9.3%, Schedule 13G/A, filed 2026-08-13); 3 more are listed above.
Who are the largest shareholders of Inhibikase Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Inhibikase Therapeutics, Inc. on this page are ADAR1 Capital Management, LLC (9.9%), Fairmount Funds Management LLC (9.9%) and Commodore Capital LP (9.9%).
When did ADAR1 Capital Management, LLC buy into Inhibikase Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from ADAR1 Capital Management, LLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 9.9%; its latest, Schedule 13G/A filed 2026-05-15, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 18 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Inhibikase Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 20, 2026 | Leadership change: Dennis Berman departs, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Inhibikase Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.